Ariel Hurley Sells 2,250 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Ariel Hurley sold 2,250 shares of the firm’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $100.00, for a total transaction of $225,000.00. Following the completion of the transaction, the insider now directly owns 14,967 shares of the company’s stock, valued at approximately $1,496,700. This trade represents a 13.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Ariel Hurley also recently made the following trade(s):

• On Thursday, December 12th, Ariel Hurley sold 1,819 shares of Blueprint Medicines stock. The stock was sold at an average price of $93.26, for a total value of $169,639.94.

Blueprint Medicines Trading Up 2.3 %

Blueprint Medicines stock traded up $2.33 during mid-day trading on Wednesday, hitting $104.89. 1,114,529 shares of the stock were exchanged, compared to its average volume of 999,285. The stock has a market capitalization of $6.66 billion, a price-to-earnings ratio of -49.71 and a beta of 0.61. Blueprint Medicines Co. has a 12 month low of $72.24 and a 12 month high of $121.90. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The firm’s fifty day simple moving average is $93.75 and its two-hundred day simple moving average is $95.29.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.08. The company had revenue of $128.20 million during the quarter, compared to analysts’ expectations of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. Blueprint Medicines’s revenue for the quarter was up 126.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($2.20) earnings per share. Analysts forecast that Blueprint Medicines Co. will post -3.68 EPS for the current year.

Wall Street Analyst Weigh In

BPMC has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a research report on Monday. StockNews.com raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, November 8th. Stephens reissued an “overweight” rating and set a $140.00 target price on shares of Blueprint Medicines in a report on Thursday, January 2nd. JPMorgan Chase & Co. initiated coverage on Blueprint Medicines in a research note on Thursday, November 14th. They issued an “overweight” rating and a $126.00 price target on the stock. Finally, UBS Group started coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They issued a “neutral” rating and a $88.00 price target on the stock. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $122.72.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in BPMC. Amalgamated Bank boosted its position in shares of Blueprint Medicines by 5.3% during the 2nd quarter. Amalgamated Bank now owns 2,154 shares of the biotechnology company’s stock valued at $232,000 after purchasing an additional 109 shares in the last quarter. Pallas Capital Advisors LLC increased its position in Blueprint Medicines by 3.2% in the 3rd quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company’s stock valued at $523,000 after buying an additional 176 shares in the last quarter. Clarus Wealth Advisors raised its position in shares of Blueprint Medicines by 8.6% during the third quarter. Clarus Wealth Advisors now owns 2,590 shares of the biotechnology company’s stock worth $231,000 after purchasing an additional 206 shares during the period. Mackenzie Financial Corp lifted its stake in shares of Blueprint Medicines by 5.2% in the second quarter. Mackenzie Financial Corp now owns 4,885 shares of the biotechnology company’s stock valued at $527,000 after buying an additional 243 shares in the last quarter. Finally, Franklin Resources Inc. increased its position in shares of Blueprint Medicines by 0.7% during the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock worth $3,259,000 after acquiring an additional 265 shares in the last quarter.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.